While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

Detailed price information for Goldman Sachs Group (GS-N) from The Globe and Mail including charting and trades.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Lilly makes tirzepatide, sold under the name Zepbound ... and moves Amazon has made to revamp its cost structure in recent years should set it on the right earnings path in the coming months ...

Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1 ... Newer GLP-1 receptor agonists like tirzepatide, (which combines a GLP-1 mimic with the mimic ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Weight loss drugs like Ozempic and wegovy have become global sensation. In the recent years, companies like Novo Nordisk and Eli Lilly have GLP-1 agonists and dual GLP-1/GIP receptor agonists that ...

Enter GetSimpli Oral Tirzepatide, a revolutionary product ... interfere with the active ingredients while providing necessary structure and consistency to the product. By maintaining a clean ...

The injected Zepbound® produced a total of 38 adverse events across the study group of 9 persons, whereas the oral DehydraTECH-tirzepatide only produced 20 adverse events, a reduction of 47%.

At least nine patients using the glucagon-like peptide 1 (GLP-1) receptor agonists semaglutide and tirzepatide developed ophthalmic complications, of whom seven had nonarteritic anterior ischemic ...